This episode of The Motley Fool's Market Checkup dives into the hottest headlines, looks at the biggest market movers in the health-care sector, and also discusses the implementation of the Affordable Care Act, also known as Obamacare.
This segment from the show focuses on Amarin (AMRN +1.21%) and its triglyceride-lowering drug Vascepa. Today, trading of Amarin's shares was halted as a highly anticipated FDA advisory committee meeting convened to discuss the proposed label expansion for Vascepa.
Investors may recall that shares of Amarin plunged 20% after the committee's briefing documents were released last week, but shares could fall further tomorrow, as the advisory committee voted 9-2 against approving Vascepa.
It's difficult to tell how the market will react to the bad news, and management is set to discuss the decision at a conference call this evening. However, in this video, analysts David Williamson and Max Macaluso look at the bear and bull theses for this stock.
Note: This video was recorded before the results from Amarin's FDA panel released its decision.
